nxera pharma co ltd - SOLTF

SOLTF

Close Chg Chg %
10.50 -0.61 -5.76%

Closed Market

9.90

-0.61 (5.76%)

Volume: 1.70K

Last Updated:

Nov 20, 2026, 11:42 AM EDT

Company Overview: nxera pharma co ltd - SOLTF

SOLTF Key Data

Open

$9.75

Day Range

9.75 - 9.90

52 Week Range

4.90 - 12.53

Market Cap

$980.63M

Shares Outstanding

91.39M

Public Float

73.44M

Beta

0.61

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.39

Yield

0.00%

Dividend

$0.08

EX-DIVIDEND DATE

Mar 27, 2015

SHORT INTEREST

N/A

AVERAGE VOLUME

200.87

 

SOLTF Performance

1 Week
 
-5.76%
 
1 Month
 
26.62%
 
3 Months
 
75.69%
 
1 Year
 
41.36%
 
5 Years
 
N/A
 

SOLTF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About nxera pharma co ltd - SOLTF

Nxera Pharma Co., Ltd. is a technology-driven biopharmaceutical company that aims to meet unmet needs in Japan and around the world and deliver new specialty medicines that improve the quality of life for patients. The firm engages in activities from discovery through to late clinical stage and commercialization, internally and in partnership with global pharma and biotech companies. It focuses on some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders, and rare diseases, and leverages the power of its GPCR targeted structure based drug discovery NxWave platform to provide a source of best- or first-in-class medicines. The company was founded by Shinichi Tamura and Takaya Nakamura on June 22, 1990 and is headquartered in Tokyo, Japan.

SOLTF At a Glance

Nxera Pharma Co., Ltd.
Midtown East
Tokyo, Tokyo 107-0052
Phone 81-3-5962-5718 Revenue 197.96M
Industry Pharmaceuticals: Major Net Income -83,756,955.75
Sector Health Technology 2025 Sales Growth 4.006%
Fiscal Year-end 12 / 2026 Employees 382
View SEC Filings

SOLTF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.406
Price to Book Ratio 1.227
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -28.728
Enterprise Value to Sales 3.599
Total Debt to Enterprise Value 0.514

SOLTF Efficiency

Revenue/Employee 518,224.793
Income Per Employee -219,259.046
Receivables Turnover 2.676
Total Asset Turnover 0.214

SOLTF Liquidity

Current Ratio 2.541
Quick Ratio 1.895
Cash Ratio 1.164

SOLTF Profitability

Gross Margin 60.662
Operating Margin -27.27
Pretax Margin -50.481
Net Margin -42.31
Return on Assets -9.059
Return on Equity -20.302
Return on Total Capital -11.09
Return on Invested Capital -10.892

SOLTF Capital Structure

Total Debt to Total Equity 94.069
Total Debt to Total Capital 48.472
Total Debt to Total Assets 41.354
Long-Term Debt to Equity 83.111
Long-Term Debt to Total Capital 42.825
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Nxera Pharma Co Ltd - SOLTF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
118.37M 90.79M 190.34M 197.96M
Sales Growth
-26.57% -23.30% +109.65% +4.01%
Cost of Goods Sold (COGS) incl D&A
13.44M 34.85M 70.68M 77.87M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
10.23M 17.62M 26.30M 29.18M
Depreciation
4.28M 6.99M 10.65M 10.57M
Amortization of Intangibles
5.95M 10.63M 15.65M 18.61M
COGS Growth
-14.87% +159.24% +102.81% +10.19%
Gross Income
104.93M 55.94M 119.66M 120.09M
Gross Income Growth
-27.84% -46.69% +113.91% +0.36%
Gross Profit Margin
+88.64% +61.62% +62.87% +60.66%
2022 2023 2024 2025 5-year trend
SG&A Expense
83.55M 120.37M 155.07M 174.07M
Research & Development
56.67M 71.65M 78.00M 96.70M
Other SG&A
26.88M 48.72M 77.07M 77.37M
SGA Growth
+1.22% +44.07% +28.82% +12.25%
Other Operating Expense
- - - -
-
Unusual Expense
13.40M 8.86M 7.98M 13.33M
EBIT after Unusual Expense
7.98M (73.29M) (43.39M) (67.31M)
Non Operating Income/Expense
8.92M 3.05M 17.74M (26.89M)
Non-Operating Interest Income
1.79M 8.71M 9.76M 6.49M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
5.44M 5.71M 5.13M 5.74M
Interest Expense Growth
+13.12% +5.05% -10.19% +11.95%
Gross Interest Expense
5.44M 5.71M 5.13M 5.74M
Interest Capitalized
- - - -
-
Pretax Income
11.46M (75.95M) (30.77M) (99.93M)
Pretax Income Growth
+228.69% -762.90% +59.48% -224.74%
Pretax Margin
+9.68% -83.66% -16.17% -50.48%
Income Tax
5.29M (24.80M) 1.16M (16.18M)
Income Tax - Current - Domestic
2.62M 1.14M 3.28M 153.74K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
2.68M (25.94M) (2.12M) (16.33M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
2.90M (51.15M) (31.94M) (83.76M)
Minority Interest Expense
- - - -
-
Net Income
2.90M (51.15M) (31.94M) (83.76M)
Net Income Growth
-68.62% -1,861.32% +37.57% -162.27%
Net Margin Growth
+2.45% -56.34% -16.78% -42.31%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
2.90M (51.15M) (31.94M) (83.76M)
Preferred Dividends
- - - -
-
Net Income Available to Common
2.90M (51.15M) (31.94M) (83.76M)
EPS (Basic)
0.0355 -0.6199 -0.3559 -0.9278
EPS (Basic) Growth
-68.86% -1,846.20% +42.59% -160.69%
Basic Shares Outstanding
81.79M 82.52M 89.73M 90.28M
EPS (Diluted)
0.0352 -0.6199 -0.3559 -0.9278
EPS (Diluted) Growth
-68.82% -1,861.08% +42.59% -160.69%
Diluted Shares Outstanding
82.59M 82.52M 89.73M 90.28M
EBITDA
31.61M (46.81M) (9.11M) (24.80M)
EBITDA Growth
-57.58% -248.10% +80.54% -172.25%
EBITDA Margin
+26.70% -51.56% -4.79% -12.53%

Nxera Pharma Co Ltd in the News